Pharmacovigilance area of interest | ||||||
---|---|---|---|---|---|---|
Activity type | Adverse events | Counterfeit drugs | Drug quality assurance | PV NOS | N/A | Total |
Behaviour change communication | 6 (85.7) | 1 (14.3) | 7 (2.4) | |||
Improve regulatory system | 1 (3.1) | 6 (18.8) | 14 (53.1) | 11 (34.4) | 32 (11.1) | |
Improving supply chain | 1 (6.7) | 7 (46.7) | 7 (46.7) | 15 (5.2) | ||
Laboratory supplies and training | 6 (15.4) | 27 (69.2) | 6 (15.4) | 39 (13.5) | ||
Operations research | 2 (66.7) | 1 (33.3) | 3 (1.0) | |||
Surveillance | 3 (8.3) | 10 (27.8) | 21 (58.3) | 2 (5.6) | 36 (12.5) | |
Training/capacity building | 1 (9.1) | 6 (54.5) | 4 (36.4) | 11 (3.8) | ||
Pharmacovigilance NOS | 2 (6.3) | 1 (3.1) | 23 (71.9) | 6 (18.8) | 32 (11.1) | |
Pharmacovigilance NOS-unfunded | 26 (100) | 26 (9.0) | ||||
Surveillance-not funded | 5 (100) | 5 (1.7) | ||||
Context onlya | 39 (100) | 39 (13.5) | ||||
Historical activityb | 12 (17.4) | 37 (53.6) | 17 (24.6) | 3 (4.4) | 69 (24.0) | |
Total | 14 (4.9) | 40 (13.9) | 154 (53.5) | 49 (17.0) | 42 (14.6) |